Table 1.
Characteristics of Study Sample During A Period Dominated by the Omicron Variant (20 December 2021 to 5 April 2022)
| Study Participants, No. (Column %)a | ||||||||
|---|---|---|---|---|---|---|---|---|
| BNT162b2 Vaccine | mRNA1273 Vaccine | |||||||
| Characteristic | Total | Unvaccinated | 2 Doses | 3 Doses | 2 Doses | 3 Doses | Symptomatic | SARS-CoV-2 PCR Positive |
| All tests, no. (row %) | 7098 (100) | 85 (1) | 2094 (30) | 3015 (42) | 916 (13) | 988 (14) | 1340 (19) | 2270 (32) |
| Female sex | 5745 (81) | 82 (96) | 1676 (80) | 2400 (80) | 779 (85) | 808 (82) | 1089 (81) | 1853 (82) |
| Location | ||||||||
| HUP | 3983 (56) | 24 (28) | 1255 (60) | 1996 (66) | 337 (37) | 371 (38) | 840 (63) | 1245 (55) |
| Presbyterian | 546 (8) | 2 (3) | 93 (4) | 125 (4) | 166 (18) | 160 (16) | 82 (6) | 206 (9) |
| PAH | 854 (12) | 6 (7) | 168 (8) | 140 (5) | 222 (24) | 318 (32) | 104 (8) | 268 (12) |
| Princeton | 943 (13) | 45 (53) | 333 (16) | 445 (15) | 70 (8) | 50 (5) | 92 (7) | 265 (12) |
| Chester | 772 (11) | 8 (9) | 245 (12) | 309 (10) | 121 (13) | 89 (9) | 222 (17) | 286 (13) |
| Age, y | ||||||||
| 18–30 | 1465 (21) | 20 (24) | 464 (22) | 649 (22) | 183 (20) | 149 (15) | 302 (23) | 526 (23) |
| 31–40 | 2454 (35) | 29 (34) | 807 (39) | 1032 (34) | 297 (32) | 289 (29) | 499 (37) | 810 (36) |
| 41–50 | 1362 (19) | 15 (18) | 436 (21) | 520 (17) | 195 (21) | 196 (20) | 268 (20) | 489 (22) |
| 51–60 | 1165 (16) | 13 (15) | 269 (13) | 500 (17) | 167 (18) | 216 (22) | 176 (13) | 318 (14) |
| >60 | 652 (9) | 8 (9) | 118 (6) | 314 (10) | 74 (8) | 138 (14) | 95 (7) | 127 (6) |
| Race/ethnicity | ||||||||
| White | 4324 (61) | 53 (62) | 1123 (54) | 2049 (68) | 481 (53) | 618 (63) | 819 (61) | 1251 (55) |
| Black | 1556 (22) | 26 (31) | 637 (30) | 381 (13) | 303 (33) | 209 (21) | 307 (23) | 627 (28) |
| Asian | 638 (9) | 0 (0) | 145 (7) | 354 (12) | 55 (6) | 84 (9) | 116 (9) | 185 (8) |
| Other | 518 (7) | 5 (6) | 165 (8) | 217 (7) | 62 (7) | 69 (7) | 86 (6) | 179 (8) |
| Latinx | 62 (1) | 1 (1) | 24 (1) | 14 (0) | 15 (2) | 8 (1) | 12 (1) | 28 (1) |
| Clinical job role | 4361 (62) | 61 (76) | 1219 (58) | 1971 (66) | 548 (60) | 562 (57) | 823 (62) | 1335 (59) |
| Time since dose 2 or 3, wk | ||||||||
| <8 | … | … | 2 (0) | 519 (17) | 1 (0) | 437 (45) | … | … |
| 8–12 | … | … | 4 (0) | 968 (32) | 0 (0) | 280 (29) | … | … |
| 12–16 | … | … | 22 (1) | 868 (29) | 10 (1) | 118 (12) | … | … |
| 16–20 | … | … | 147 (7) | 293 (10) | 34 (4) | 78 (8) | … | … |
| 20–24 | … | … | 201 (10) | 243 (8) | 28 (3) | 27 (3) | … | … |
| >24 | … | … | 1718 (82) | 124 (4) | 843 (92) | 25 (3) | … | … |
Abbreviations: Chester, Chester County Hospital; HUP, Hospital of the University of Pennsylvania; PAH, Pennsylvania Hospital; PCR, polymerase chain reaction; Presbyterian, Penn Presbyterian Medical Center; Princeton, Princeton Health; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Data represent no. (column %) of study participants unless otherwise specified.